Is serum uric acid a predictive factor of response to IFN‐treatment in patients with chronic hepatitis C infection?

Pellicano, Rinaldo; Puglisi, Giovanni; Ciancio, Alessia; Balzola, F.; Saracco, Giorgio Maria; Ciccone, Giovannino; Baldi, Ileana; Abate, Maria Lorena; Smedile, Antonina; Rizzetto, M.

doi:10.1002/jmv.21123

Cited by 14 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Basal plasma uric acid levels were available in 185 patients (Table I), without significant differences between the 102 who achieved SVR and the 83 primary non-responders (Table I). The cut-off point for serum uric acid ≥ 5.8 proposed by Pellicano et al (16) had no predictive role of response in our study, as SVR was obtained by 56.7% and 53.1% of patients under and over the cut off value, respectively.…”

Section: Resultscontrasting

confidence: 73%

See 1 more Smart Citation

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1

Cuenca

Fernández

Devesa

et al. 2010

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Background and aims: more than half of patients with genotype 1 chronic hepatitis C (CHC) do not achieve a sustained viral response (SVR) to current antiviral therapy due to primary non-response, relapse or intolerance. Factors related to each of these unfavorable outcomes are different and the last two may be partially prevented. Our aim was to identify basal criteria to predict the risk of primary failure. Patients and methods: we included 251 consecutive patients (152 males) from a single centre, infected with HCV genotype 1 and not previously treated. SVR was achieved in 141 patients and primary failure in 110. Results: high vs. low viral load (> 400,000 IU/mL, OR = 6.17; 95% CI: 2.50-15.23), high serum GGT (> 60 IU/mL, OR = 4.25; 95% CI: 2.49-7.24), low serum cholesterol (< 178 mg/dL, OR = 2.93; 95% CI: 1.75-4.92) and older age (> 47 yrs., OR = 1.79; 95% CI: 1.08-2.96) were associated to the risk of primary failure in the lineal logistic regression analysis. From the 58 patients carrying all the first three negative criteria, 46 (79.3%) were primary non-responders. Conclusions: the negative basal profile identified in this study is based on easily available data and provides information about the risk of primary therapeutic failure, and may help to decide whether antiviral therapy should be offered to a single patient.

show abstract

Section: Resultscontrasting

confidence: 73%

“…This drawback explains why we can not discuss the role of insulin resistance, which seems very important in determining the failure of antiviral therapy (22,33). However, our results did not confirm the suggested relation between the chance of SVR and basal values for serum uric acid (16) and neutrophil count (34,35).…”

Section: Discussioncontrasting

confidence: 62%

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1

Cuenca

Fernández

Devesa

et al. 2010

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

show abstract

“…We found high UA levels in chronic viral hepatitis (8.51 ± 2.7 mg/dl). A study from Italy has found that high UA levels are associated with poor outcome in chronic viral hepatitis 9 . This may be because high UA indicates ongoing hepatocellular destruction.…”

Section: Discussionmentioning

confidence: 99%

Study of Serum Uric Acid in Chronic Liver Disease and Its Relation With Other Parameters

Paul¹,

Chakravarti²,

Mandal³

et al. 2013

Int. Res. J. Pharm.

View full text Add to dashboard Cite

In chronic liver disease, high uric acid levels are independently associated with severe disease and poor prognosis. However, studies regarding the relation of uric acid levels with different parameters of liver dysfunction are rare from India. Our aim was to study uric acid (UA) levels in chronic liver disease and find any association of UA with different blood parameters and prognosis. We selected patients of chronic liver disease of any etiology. We did the serum UA test along with full liver function tests. Child Turcot Pugh (CTP) score was calculated for each patient. Then by suitable statistical tests, any association or correlation was studied. We had total of 52 patients with 31 % female. 19 (36.5 %) of the cases had liver disease secondary to alcoholism followed by 15 cases of non alcoholic fatty liver disease. 69.2 % of the patients were in CTP class B or C. Serum UA levels were significantly higher in chronic viral hepatitis cases (p<0.001). UA levels showed significant correlation with serum bilirubin (r=0.567), SGOT (r=0.464) and mortality. The UA levels showed significant correlation with severe disease and mortality. However, whether UA can be included in risk stratification of chronic liver disease can only be determined by larger randomized trials.

show abstract

“…Nevertheless, uric acid showed better predictive value than many other variables that have been reported as predictors for treatment response. Previously, Pellicano et al [ 22 ] reported that uric acid was a predictive factor of IFN treatment response for HCV-infected patients. Other studies have demonstrated a significant relationship between hyperuricemia and insulin resistance [ 23 , 24 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection

Won

Kim

et al. 2017

Korean J Intern Med

View full text Add to dashboard Cite

Background/AimsCombined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection. Many predictive factors for treatment response have been identified. The aim of this study was to evaluate the efficacy and safety of combined PEG-IFN plus RBV and to examine the value of serum uric acid as a predictive factor in the treatment of chronic hepatitis C.MethodsA total of 74 patients chronically infected with HCV were enrolled between December 2004 and June 2009. Patients received subcutaneous PEG-IFN (α-2a: 180 μg once a week) in combination with RBV (1,000 to 1,200 mg daily depending on body weight). We evaluated treatment responses represented by early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and relapse, as well as diverse adverse events. Various viral and host features were also assessed to clarify factors associated with treatment response.ResultsDuring treatment, EVR was achieved in 26 patients (26/33, 78.8%) with HCV genotype 1. ETR and SVR were achieved in 59 (77.6%) and 56 patients (73.6%), respectively, across all genotypes. Genotype 2/3, lower HCV RNA, and lower uric acid were associated with higher SVR.ConclusionsThe treatment response to combination therapy with PEG-IFN plus RBV was effective, especially in genotype 2/3. Uric acid might be useful as a predictive factor for response to therapy for chronic hepatitis.

show abstract

Is serum uric acid a predictive factor of response to IFN‐treatment in patients with chronic hepatitis C infection?

Cited by 14 publications

References 20 publications

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1

Predictive baseline criteria of primary therapeutic failure in chronic hepatitis C genotype 1

Study of Serum Uric Acid in Chronic Liver Disease and Its Relation With Other Parameters

Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection

Contact Info

Product

Resources

About